Over the past week at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, we have been reminded that Latin America is one of the few global regions where new HIV cases have continued to rise since 2010, even though pre-exposure prophylaxis (PrEP) has been available for more than a decade.
However, scaling up of oral PrEP has been slow in this region. Additionally, those on PrEP have experienced adherence challenges. HIV disproportionately impacts young people and sexual and gender minorities, such as gay and bisexual men, transgender and non-binary people in Latin America. Black and mixed race people are also disproportionately impacted.
Long-acting injectable PrEP – in the form of cabotegravir (CAB-LA), administered every two months – has the potential to reshape the Latin American epidemic. In the ImPrEP cohort in Brazil, there were no new cases of HIV amongst 1200 people taking CAB-LA. These encouraging results were presented by Dr Beatriz Grinsztejn, Director of the HIV/AIDS Clinical Research Unit at the Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, and the current president of the International AIDS Society.
Read the full news story at aidsmap.
View all aidsmap reports from CROI 2025
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.